Work

STARLITE 2: Phase 2 study of nivolumab plus 177Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps4603

Authors: Darren R. Feldman, Robert J. Motzer, Andrea Knezevic, Chung-Han Lee, Martin H Voss, Serge K. Lyashchenko, Hijin Park, Steven M. Larson, Neeta Pandit-Taskar

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286297445

Cites:

Cited by: 11

Related to: 10